ACAD
31.96
+1.59
+5.24%
AEMD
0.215
+0.005
+2.1429%
APRI
1.91
-0.01
-0.78%
ARNA
4.33
-0.01
-0.23%
ATEC
1.4
0.00
0.00%
CNAT
7.75
+0.99
+14.64%
CRXM
0.195
+0.002
+1.1837%
CYTX
1.19
+0.01
+0.85%
DXCM
60.16
+1.79
+3.07%
GNMK
13.29
+0.2
+1.53%
HALO
13.93
+0.62
+4.66%
ILMN
187.17
+2.8
+1.52%
INNV
0.13
-0.019
-12.8600%
INO
8.285
+0.195
+2.410%
ISCO
0.061
+0.003
+6.087%
ISIS
63.37
+2.22
+3.63%
LGND
72.95
+2.65
+3.77%
LPTN
2.48
-0.04
-1.59%
MBVX
1.62
-0.13
-7.43%
MEIP
1.74
-0.09
-4.92%
MNOV
3.55
+0.23
+6.93%
MRTX
28.42
+2.05
+7.77%
MSTX
0.499
-0.021
-4.038%
NBIX
38.78
+1.45
+3.88%
NUVA
44.6
+0.62
+1.41%
ONCS
0.35
+0.01
+3.40%
ONVO
3.66
-0.27
-6.87%
OREX
7.54
+0.29
+4.00%
OTIC
34.23
+0.47
+1.39%
QDEL
27.15
+0.63
+2.38%
RCPT
147.43
+8.44
+6.07%
RGLS
16.82
+0.26
+1.57%
RMD
71.55
+1.3
+1.85%
SCIE
0.031
0.00
0.00%
SPHS
0.59
+0.05
+9.2407%
SRNE
12.29
+0.44
+3.71%
TROV
7
+0.23
+3.40%
VICL
0.923
+0.068
+7.9181%
VOLC
17.99
0.00
0.00%
ZGNX
1.34
+0.03
+2.29%
ACAD
31.96
+1.59
+5.24%
AEMD
0.215
+0.005
+2.1429%
APRI
1.91
-0.01
-0.78%
ARNA
4.33
-0.01
-0.23%
ATEC
1.4
0.00
0.00%
CNAT
7.75
+0.99
+14.64%
CRXM
0.195
+0.002
+1.1837%
CYTX
1.19
+0.01
+0.85%
DXCM
60.16
+1.79
+3.07%
GNMK
13.29
+0.2
+1.53%
HALO
13.93
+0.62
+4.66%
ILMN
187.17
+2.8
+1.52%
INNV
0.13
-0.019
-12.8600%
INO
8.285
+0.195
+2.410%
ISCO
0.061
+0.003
+6.087%
ISIS
63.37
+2.22
+3.63%
LGND
72.95
+2.65
+3.77%
LPTN
2.48
-0.04
-1.59%
MBVX
1.62
-0.13
-7.43%
MEIP
1.74
-0.09
-4.92%
MNOV
3.55
+0.23
+6.93%
MRTX
28.42
+2.05
+7.77%
MSTX
0.499
-0.021
-4.038%
NBIX
38.78
+1.45
+3.88%
NUVA
44.6
+0.62
+1.41%
ONCS
0.35
+0.01
+3.40%
ONVO
3.66
-0.27
-6.87%
OREX
7.54
+0.29
+4.00%
OTIC
34.23
+0.47
+1.39%
QDEL
27.15
+0.63
+2.38%
RCPT
147.43
+8.44
+6.07%
RGLS
16.82
+0.26
+1.57%
RMD
71.55
+1.3
+1.85%
SCIE
0.031
0.00
0.00%
SPHS
0.59
+0.05
+9.2407%
SRNE
12.29
+0.44
+3.71%
TROV
7
+0.23
+3.40%
VICL
0.923
+0.068
+7.9181%
VOLC
17.99
0.00
0.00%
ZGNX
1.34
+0.03
+2.29%
Home » Archive by Category

Syndication

Patent Prosecution Attorney or Agent – Sallie Hamilton Personnel – San Diego, CA

March 23, 2015 – 1:57 pm

The ideal candidate will have 1 – 5 years of experience in the following areas:. Patent Prosecution Associate Attorney or Agent – Chemistry/Biotech….
From Indeed – 23 Mar 2015 20:57:05 GMT
– View all San Diego jobs

MEI Pharma’s Cancer Drug Pracinostat Fails Phase 2 Trials

March 23, 2015 – 1:42 pm

Shares of MEI Pharma Inc. lost more than two-thirds of their value Monday after the San Diego biotech said its cancer drug Pracinostat failed a Phase 2 clinical trial.

Quality Assurance Supervisor (El Cajon)

March 23, 2015 – 12:48 pm

Scantibodies Biologics in El Cajon is looking to add a talented Quality Assurance Supervisor to our growing team. The objective of the position is to ensure that Scantibodies Biologics’ plasma collection centers operate in compliance with all quality […

Quality Assurance Supervisor (El Cajon)

March 23, 2015 – 12:48 pm

Scantibodies Biologics in El Cajon is looking to add a talented Quality Assurance Supervisor to our growing team. The objective of the position is to ensure that Scantibodies Biologics’ plasma collection centers operate in compliance with all quality […

Product Development Associate 3 (Pacific Beach)

March 23, 2015 – 12:08 pm

Function/Scope:
The Development Associate 3 will be responsible, without daily supervisorial contact, for the preparation and interpretation of scientific assay or process development experiments relating to bioreactor development, product testing, […

Product Development Associate 3 (Pacific Beach)

March 23, 2015 – 12:08 pm

Function/Scope:
The Development Associate 3 will be responsible, without daily supervisorial contact, for the preparation and interpretation of scientific assay or process development experiments relating to bioreactor development, product testing, […

In Anorexia Nervosa, Brain Responds Differently to Hunger Signals

March 23, 2015 – 11:59 am

Researchers at the University of California, San Diego School of Medicine have pinpointed differences in brain function that may help to explain how people with anorexia nervosa can continue to starve themselves, even when already emaciated. The findin…

New goBalto Activate Solution Further Accelerates Clinical Studies

March 23, 2015 – 11:31 am

Global pharma companies and CROs use goBalto to shorten clinical study startup

SAN FRANCISCO, March 23, 2015 /PRNewswire/ — goBalto, Inc., the leading provider of cloud-based clinical study startup solutions, today announced its latest version of goBalto Activate. This first major release of 2015 offers new features that further accelerate clinical study startup.

Sponsors and CROs continue to search for ways to reduce the time it takes to get investigative sites up and running. goBalto is at the forefront of fully automating study startup, enabling business process agility and continual process improvements that existing systems don’t address.

Recognizing that study startup is more than just documents, goBalto tailored this new Activate release to include submissions and other key activities and milestones not effectively managed with existing clinical systems. To better optimize the entire startup life cycle, Activate provides a more complete and accurate picture of status and bottlenecks.

With over 1,200 CRO and pharmaceutical users in more than 50 countries using Activate to manage, track, and complete study startup tasks, goBalto has the largest set of proven country workflows. These workflows meet the expectations of specific country regulatory submission requirements out of the box, so that companies can start their studies in days.

Activate customers report improved business performance and shorter cycle times. New capabilities just released aim to reduce study startup timelines even more, with a focus on enhanced document management, business process improvement, and alerting. Activate’s new features include:

  • expired document management
  • alerts that highlight opportunities to improve cycle times and track activities and milestones
  • automated workflows that drive the entire process until documents are ready for eTMF filing
  • ability for sites to complete activities in seconds using the new Activate LITE interface
  • an API enhancement to support seamless integration with investigator portals

There continues to be a steady increase in enterprise Activate usage, with newly added top 20 pharma and biotech companies starting their first studies in Activate. The addition of goBalto‘s latest customers represents a 60 percent increase from the same time in 2014.

“Our goal is to continue to support customers who are taking the leadership role to improve study startup,” said goBalto CEO Sujay Jadhav. “We’re constantly looking for the most innovative ways to provide customers with even more time savings, increased visibility, and enhanced collaboration. With Activate’s seamless integration capabilities, we’re helping our customers span the entire study startup life cycle, out of the box, from document approval to eTMF ready.”

About goBalto
goBalto develops next-generation solutions that simplify and accelerate clinical study startup in the pharmaceutical, biotechnology, and medical device industries. Our management team has over 100 years of combined experience in the life sciences industry and enterprise software implementation. Our team has worked for such companies as Amgen, Genentech, Roche, Johnson & Johnson, and Model N. With a proven commitment to customer success, disruption, and study startup optimization, we’re changing the way our leading global pharma and CRO customers approach their business processes. Based in San Francisco, California, we have satellite offices in Pennsylvania and Singapore. For more information, visit www.gobalto.com.

Press contacts:
Maria Breaux
415.671.4372
mbreaux@gobalto.com

Amanda Jones
Connect Marketing
801-373-7888
amandaj@connectmarketing.com

Logo – http://photos.prnewswire.com/prnh/20141118/159334LOGO

 

 

SOURCE goBalto, Inc.

Environmental Specialist I/II (Stormwater) (City of Vista)

March 23, 2015 – 11:10 am

THE POSITION: Under general supervision, this position will be accountable for coordinating and implementing components of the City’s stormwater management program, consistent with requirements of Regional Water Quality Control Board Order No. R9-201 […

10 facts about multiple sclerosis

March 23, 2015 – 11:03 am

Multiple sclerosis is the most common neurological disease in young adults, usually striking between the ages of 20 and 40 years.